Neural tolerance of iotrolan 300 in ascending cervical myelography: results of a multicenter study.
This study examined the opacification, dose, and tolerance of iotrolan 300 on 231 patients in ascending cervical myelography. The contrast was rated good in 188 (81.4%) of the cases and satisfactory in 40 (17.3%) of the cases. The contrast was poor in only three (1.3%) cases. In 152 patients a dose of 10 ml or less of iotrolan 300 was administered. A good contrast quality was obtained in 84.2% of all examinations. From a total of 231 patients, 146 exhibited no concomitant effects. The intensity of the headache and neck ache was recorded by the patients themselves by means of an analog scale. The frequency and degree of the postmyelographic complaints did not increase with higher doses, i.e., they were not dose dependent. Neurologic irritation, in the form of radicular symptoms, appeared in only 2 of 231 examinations. These data demonstrate that iotrolan 300 is excellent for use in ascending cervical myelography.
Behrends
B
B
Albrecht
A
A
Bingas
B
B
Becker
H
H
Brunke
J
J
von Einsiedel
H
H
Mariss
G
G
Schmidt
K
K
Thun
F
F
Valavanis
A
A
D000328:Adult; D000368:Aged; D002574:Cervical Vertebrae / Q000000981:diagnostic imaging*; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007405:Intervertebral Disc Displacement / Q000000981:diagnostic imaging; D007463:Iodobenzoates / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009192:Myelography; D013125:Spinal Neoplasms / Q000000981:diagnostic imaging; D014283:Triiodobenzoic Acids / Q000009:adverse effects*
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; C033300:iotrolan